Fox Z - Search Results

1

Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field.

Wittkop L, Smith C, Fox Z, Sabin C, Richert L, Aboulker JP, Phillips A, Chêne G, Babiker A, Thiébaut R; NEAT-WP4. Wittkop L, et al. Among authors: fox z. Clin Trials. 2010 Feb;7(1):19-35. doi: 10.1177/1740774509356117. Clin Trials. 2010. PMID: 20156955 Review.

2

Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial.

Raffi F, Babiker AG, Richert L, Molina JM, George EC, Antinori A, Arribas JR, Grarup J, Hudson F, Schwimmer C, Saillard J, Wallet C, Jansson PO, Allavena C, Van Leeuwen R, Delfraissy JF, Vella S, Chêne G, Pozniak A; NEAT001/ANRS143 Study Group. Raffi F, et al. Lancet. 2014 Nov 29;384(9958):1942-51. doi: 10.1016/S0140-6736(14)61170-3. Epub 2014 Aug 4. Lancet. 2014. PMID: 25103176 Clinical Trial.

3

Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy.

Geretti AM, Fox ZV, Booth CL, Smith CJ, Phillips AN, Johnson M, Li JF, Heneine W, Johnson JA. Geretti AM, et al. J Acquir Immune Defic Syndr. 2009 Dec;52(5):569-73. doi: 10.1097/QAI.0b013e3181ba11e8. J Acquir Immune Defic Syndr. 2009. PMID: 19779307

4

Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen.

Fox Z, Phillips A, Cohen C, Neuhaus J, Baxter J, Emery S, Hirschel B, Hullsiek KH, Stephan C, Lundgren J; SMART Study Group. Fox Z, et al. AIDS. 2008 Nov 12;22(17):2279-89. doi: 10.1097/QAD.0b013e328311d16f. AIDS. 2008. PMID: 18981767 Free PMC article. Clinical Trial.

5

Rate of CD4 decline and HIV-RNA change following HIV seroconversion in men who have sex with men: a comparison between the Beijing PRIMO and CASCADE cohorts.

Huang X, Lodi S, Fox Z, Li W, Phillips A, Porter K, Lutsar I, Kelleher A, Li N, Xu X, Wu H, Johnson AM; Beijing PRIMO cohort study; CASCADE Collaboration in EuroCoord. Huang X, et al. Among authors: fox z. J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):441-6. doi: 10.1097/QAI.0b013e31827f5c9a. J Acquir Immune Defic Syndr. 2013. PMID: 23221982

6

Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection.

Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB, Phillips AN; INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Rodger AJ, et al. Among authors: fox z. J Infect Dis. 2009 Sep 15;200(6):973-83. doi: 10.1086/605447. J Infect Dis. 2009. PMID: 19678756 Free PMC article. Clinical Trial.

7

Predicting antiretroviral drug resistance from the latest or the cumulative genotype.

Garcia F, Alvarez M, Fox Z, Garcia-Diaz A, Guillot V, Johnson M, Chueca N, Phillips A, Hernández-Quero J, Geretti AM. Garcia F, et al. Among authors: fox z. Antivir Ther. 2011;16(3):373-82. doi: 10.3851/IMP1753. Antivir Ther. 2011. PMID: 21555820

8

The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors.

Fox ZV, Geretti AM, Kjaer J, Dragsted UB, Phillips AN, Gerstoft J, Staszewski S, Clotet B, von Wyl V, Lundgren JD. Fox ZV, et al. AIDS. 2007 Oct 1;21(15):2033-42. doi: 10.1097/QAD.0b013e32825a69e4. AIDS. 2007. PMID: 17885293 Clinical Trial.

9

Predictors of having a resistance test following confirmed virological failure of combination antiretroviral therapy: data from EuroSIDA.

Fox ZV, Cozzi-Lepri A, D'Arminio Monforte A, Karlsson A, Phillips AN, Kronborg G, Kjaer J, Clotet B, Lundgren JD; EuroSIDA. Fox ZV, et al. Antivir Ther. 2011;16(5):781-5. doi: 10.3851/IMP1801. Antivir Ther. 2011. PMID: 21817201 Free article.

10

A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial.

Fox Z, Dragsted UB, Gerstoft J, Phillips AN, Kjaer J, Mathiesen L, Youle M, Katlama C, Hill A, Bruun JN, Clumeck N, Dellamonica P, Lundgren JD; COLATE study group. Fox Z, et al. Antivir Ther. 2006;11(6):761-70. Antivir Ther. 2006. PMID: 17310820 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

140 results

Search Page